Corporate News

Statement re. media comment

08 February 2021

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the article published online yesterday by the Financial Times.

The Company can confirm that it is continuing to modify its Alva-based facility to upscale significantly its lateral flow test production capacity. When contracts or supply agreements are signed to utilise this capacity the Company will announce this in line with AIM disclosure obligations.

 

Contacts:  

Omega Diagnostics Group PLC Tel: 01259 763 030
Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director  
  
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane (ECM)  
  
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303

 

share price

Latest Share Price

investor news

Investor News

Sign up for Investor Alerts